Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2021-09-30
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevalence and Risk Factors of Hyperkalemia in Non-Dialysis Chronic Kidney Disease Patients in Community
NCT06940414
Risk Factors and Machine Learning Model for Diuretics Related Acute Kidney Injury
NCT05527054
Screening and Assessing the Risk Factors and Complications of Chronic Kidney Disease
NCT03246191
Risk Factors of Postoperative Acute Kidney Injury and Mortality Among Hospitalized Patients Undergoing Major Surgery
NCT07136194
Chronic Kidney Disease Registry Platform Study
NCT06117852
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
For HD centers:
* ≥ 100 patients under MHD within 3 years prior the study initiation
* Willing to participate in the study
* Have routine blood collection after LIDI
* Have death records
For HD patients:
• On chronic HD for ≥ 3 months
Exclusion Criteria
* Unable to provide detailed data required by study protocol
* Being unable to comply with study-specified procedure
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Peking University People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Li Zuo
Head of the Nephrology Department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Li Zuo
Role: PRINCIPAL_INVESTIGATOR
Peking University People's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Xinju Z, Changying X, Hong L, Guisen L, Ping Z, Caili W, Zuying X, Gang X, Rong W, Rongshan L, Aili J, Hongli J, Jianxin W, Xiaoling W, Jing Y, Li Y, Pei W, Rui Z, Yunhua L, Huimin L, Jinsheng X, Menghua C, Yinhui L, Qinkai C, Zhongfei Y, Yan Z, Hong L, Wenbo H, Chen L, Zhaohui N, Lingling G, Li Z. Prevalence, practice pattern, and mortality of hyperkalemia in Chinese patients undergoing hemodialysis in the visualize HD study. Sci Rep. 2025 Jul 1;15(1):22405. doi: 10.1038/s41598-025-92609-1.
Zhao X, Zuo L. Multicentre, observational, retrospective cohort of hyperkalaemia burden at haemodialysis facility-level in China: the Visualize-HD study protocol. BMJ Open. 2023 Sep 21;13(9):e066394. doi: 10.1136/bmjopen-2022-066394.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20-20591
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.